{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.7","upperLimit":"80.1","value":"60.9"},{"groupId":"OG001","lowerLimit":"35.8","upperLimit":"80.0","value":"57.9"},{"groupId":"OG002","lowerLimit":"15.7","upperLimit":"54.9","value":"35.3"},{"groupId":"OG003","lowerLimit":"59.4","upperLimit":"94.6","value":"77.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"22"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate 5-year OS, defined as the time from study enrollment to death from any cause, or to date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"SPNET patients who received regimen A (no carboplatin / no isotretinoin)","id":"OG000","title":"Regimen A (SPNET Patients)"},{"description":"SPNET patients who received regimen B (carboplatin / no isotretinoin)","id":"OG001","title":"Regimen B (SPNET Patients)"},{"description":"SPNET patients who received regimen C (no carboplatin / isotretinoin)","id":"OG002","title":"Regimen C (SPNET Patients)"},{"description":"SPNET patients who received regimen D (carboplatin / isotretinoin)","id":"OG003","title":"Regimen D (SPNET Patients)"}],"paramType":"NUMBER","populationDescription":"Eligible SPNET patients are included.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percent Probability of Overall Survival (OS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)","type":"SECONDARY","unitOfMeasure":"Percent Probability"}